Attana AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Attana AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011788
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Attana AB (Attana) develops, manufactures and markets reagent kits and chip surfaces. The company offers products such as instruments, chip surfaces, reagents, kits and consumables; softwares, and accessories and spare parts. Its services comprise contract research, instrument training, attana demo, proof of principle studies, assay development services, service and support agreements; application support, attana in-house visits and technical support services. Its products are used in cell-based assay, biochemical assay, accessibility, off-target interaction, avidity, kinetics and affinity; crude sample analysis, serum sample analysis, sandwich pair selection, hybridoma screening and other applications. Attana is headquartered in Stockholm, Sweden.

Attana AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Attana AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Attana AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Attana AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Attana AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Attana AB, Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Tecan Extends Distribution Agreement With Attana 9
Attana Enters Into Distribution Agreement With Layerlab For memLayer 10
Tecan Enters Into Distribution Agreement With Attana 11
Attana AB – Key Competitors 12
Attana AB – Key Employees 13
Attana AB – Locations And Subsidiaries 14
Head Office 14
Recent Developments 15
Government and Public Interest 15
Nov 16, 2017: Attana, Karoliniska Universitetssjukhuset and KTH receives project grant of 4.8 MSEK 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Attana AB, Pharmaceuticals & Healthcare, Key Facts 2
Attana AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Attana AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Attana AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Attana AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Attana AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Tecan Extends Distribution Agreement With Attana 9
Attana Enters Into Distribution Agreement With Layerlab For memLayer 10
Tecan Enters Into Distribution Agreement With Attana 11
Attana AB, Key Competitors 12
Attana AB, Key Employees 13

★海外企業調査レポート[Attana AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EVN AG:発電所・企業SWOT分析
    EVN AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Lockheed Martin Australia Pty Ltd:企業の戦略・SWOT・財務情報
    Lockheed Martin Australia Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Australia Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • CytoSorbents Corp (CTSO):企業の財務・戦略的SWOT分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …
  • Shun Tak Holdings Ltd (242):企業の財務・戦略的SWOT分析
    Shun Tak Holdings Ltd (242) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Mahindra & Mahindra Limited:戦略・SWOT・企業財務分析
    Mahindra & Mahindra Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra & Mahindra Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • HOCHTIEF Aktiengesellschaft:企業のM&A・事業提携・投資動向
    HOCHTIEF Aktiengesellschaft - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HOCHTIEF Aktiengesellschaft Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Torii Pharmaceutical Co Ltd (4551)-製薬・医療分野:企業M&A・提携分析
    Summary Torii Pharmaceutical Co Ltd (Torii) a subsidiary of Japan Tobacco Inc is a healthcare product provider that manufactures and markets products such as antebate ointment, antebate cream and urinorm used for the treatment of hyperuricemia and gout. The company offers products for the treatment …
  • Nongshim Co. Ltd.:企業の戦略・SWOT・財務情報
    Nongshim Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nongshim Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Harbin Gloria Pharmaceuticals Co Ltd (002437)-製薬・医療分野:企業M&A・提携分析
    Summary Harbin Gloria Pharmaceuticals Co Ltd (Harbin Gloria) is a pharmaceutical company that produces and markets nutritional drugs. The company’s products comprise pharmaceutical drugs for treating nutrition disorders, cardiovascular diseases, cancer and musculoskeletal disorders. Its pipeline pro …
  • Ferno-Washington Inc:企業の戦略的SWOT分析
    Ferno-Washington Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Oncolytics Biotech Inc (ONC)-製薬・医療分野:企業M&A・提携分析
    Summary Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product, Reolysin, a formulation of the human reovirus, is at Phase II clinical trials indi …
  • Hebei Construction Group Co Ltd (1727):企業の財務・戦略的SWOT分析
    Hebei Construction Group Co Ltd (1727) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Alberta Investment Management Corporation:企業の戦略・SWOT・財務情報
    Alberta Investment Management Corporation - Strategy, SWOT and Corporate Finance Report Summary Alberta Investment Management Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • NEX Group plc.:企業の戦略的SWOT分析
    NEX Group plc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • NIKE Inc:戦略・SWOT・企業財務分析
    NIKE Inc - Strategy, SWOT and Corporate Finance Report Summary NIKE Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • UCB SA (UCB)-医療機器分野:企業M&A・提携分析
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Arthrex Inc:企業の戦略的SWOT分析
    Arthrex Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Eagle Cement Corporation (EAGLE):企業の財務・戦略的SWOT分析
    Eagle Cement Corporation (EAGLE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • PetroRio SA (PRIO3):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroRio SA (PetroRio), formerly HRT Participacoes em Petroleo SA, a subsidiary of HRT Oil & Gas Ltd, is oil and gas company that offers investment and recovering of oil production assets. The company offers development of solid growth platforms aiming to generate value to its shareholders b …
  • LPL Financial Holdings Inc (LPLA):企業の財務・戦略的SWOT分析
    LPL Financial Holdings Inc (LPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆